Keyword: Stada Arzneimittel
GSK is selling 15 OTC drugs, mainly in Europe, for an undisclosed amount as the British pharma prepares for a consumer health spinoff.
Amgen pays $2.7 billion for a 20.5% stake in BeiGene. AstraZeneca tightens its ties to China as China approves a controversial Alzheimer's drug.
In the largest acquisition in Stada's history, the German generics maker is laying out $660M for 20 Takeda drugs in the Commonwealth states.
There are five or six potential deals similar to Takeda's mooted European sale Stada could go after, CEO Peter Goldschmidt said.
The Upsa unit could fit into Stada's new growth strategy, which includes more focus on international marketing of OTC products.
Takeda made two R&D deals, China's crackdown on pollution causes pharma supply issues, Merck KGaA plans production expansions in Asia.
China has closed thousands of manufacturing plants as it tries to reduce air pollution, and one pharma company says it has created supply problems.
Perrigo is looking toward some M&A, with its eye on the consumer health business that Germany’s Merck KGaA has put on the auction block.
Last week, an activist investor held out on the buyout offer for Stada—and it worked.
Hoping to land on its feet after a tough year, Stada will soon be under new leadership.